enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Hope for Parkinson’s disease symptoms is found in ... - AOL

   www.aol.com/finance/hope-parkinson-disease...

   A new drug has shown promise in alleviating symptoms. (Getty Images) Tavapadon, a drug being tested to treat early Parkinson's disease, ... for the treatment of Parkinson's disease. With these ...

3. A Potential Parkinson's Treatment Has Promising Results - AOL

   www.aol.com/potential-parkinsons-treatment...

   A small new trial published in the journal Nature Medicine describes what would be two firsts for Parkinson's disease, if they pan out: a diagnostic test and a potential immune-based treatment ...

4. FDA Approves AbbVie's Parkinson's Treatment, Medicare ... - AOL

   www.aol.com/finance/fda-approves-abbvies...

   On Thursday, the FDA approved AbbVie Inc’s (NYSE:ABBV) Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations ...

5. With significant clinical results published in the Nature ...

   lite.aol.com/tech/story/0022/20250127/1001045145.htm

   Direct access to the brain to introduce the missing neurotransmitter at the right dose in the right place - close to the striatum - marks a decisive turning point in the therapeutic management of Parkinson's disease and will most likely lead to a revision of the disease treatment guidelines as we learn more about how this new therapeutic ...

6. Management of Parkinson's disease - Wikipedia

   en.wikipedia.org/wiki/Management_of_Parkinson's...

   In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...

7. Tavapadon - Wikipedia

   en.wikipedia.org/wiki/Tavapadon

   Tavapadon (developmental code names CVL-751, PF-06649751) is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. [2] [3] [4] It is under development by Cerevel Therapeutics, which acquired tavapadon from Pfizer in 2018. [2]